Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety
Author:
- 19 December 2008
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 9 (2) , 255-261
Abstract
Background: Fabry disease is an X-linked disease caused by the deficiency of the lysosomal enzyme α-galactosidase A. The lack of enzyme activity leads to progressive depositions of undegraded glycolipids in a great number of organs, resulting in a multisystemic disorder. Objectives: Enzyme replacement therapy is available for patients with Fabry disease. Two enzyme preparations have been approved in the European Union by the European Agency for the Evaluation of Medicinal Products (EMEA): agalsidase beta (Fabrazyme®, Genzyme Corporation), produced in Chinese hamster ovary cells; and agalsidase alfa (Replagal®, Shire Human Genetic Therapies, Inc.), produced in human cell lines. Methods: This review details the latest reports regarding the clinical efficacy and tolerability of agalsidase alfa in patients with Fabry disease. Results: Agalsidase alfa was shown to be effective in treating pain and in reducing heart size in patients with Fabry disease, to stabilize kidney function and to improve hearing, sweati...Keywords
This publication has 37 references indexed in Scilit:
- Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperonePharmacogenetics and Genomics, 2008
- Stop-codon read-through for patients affected by a lysosomal storage disorderTrends in Molecular Medicine, 2006
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006
- Thirty-four novel mutations of the GLA gene in 121 patients with Fabry diseaseHuman Mutation, 2005
- A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry diseaseGlycobiology, 2003
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001
- Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotesJournal of Inherited Metabolic Disease, 2001
- The frequency of lysosomal storage diseases in The NetherlandsHuman Genetics, 1999
- Prevalence of Lysosomal Storage DisordersJAMA, 1999